Introduction: Studies comparing direct-acting insulin analogs (DAIs) in terms of effectiveness
INTRODUCTION
Direct-acting insulin analogs (DAIs) are a cornerstone of contemporary type 1 diabetes treatment [1] . Insulin lispro was approved for use in the mid-1990s, making it the first DAI to enter the market. Insulin aspart became available in 1999 and insulin glulisine in 2004. Both before and after approval of each DAI, many clinical trials and studies have shown non-inferiority and some clinical advantages over ordinary human insulin, including fewer doses, increased flexibility, less hypoglycemia, and greater cost-effectiveness [2, 3] . Only a few studies have directly compared the clinical efficacy of various DAIs [4, 5] and none have addressed cardiovascular safety.
Long-term, real-life safety data concerning the impact of DAIs on hard endpoints, such as cardiovascular events (CVEs) and mortality are lacking, particularly among elderly patients and those with renal impairment. The aim of this study was to explore the long-term effectiveness on glycemic control, weight, and safety of DAIs in routine clinical practice among patients with type 1 diabetes, particularly elderly patients and those with renal impairment. We conducted a population-based longitudinal cohort study linking data from the Swedish National Diabetes Register (NDR) with other databases to capture information about hospitalization and cause of death.
METHODS
The Regional Ethical Review Board in Gothenburg approved the study, which was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2013. All patients gave their informed consent prior to inclusion.
Databases
The NDR was launched in 1996 to enable local quality control and regional benchmarking against national treatment guidelines [6] .
Physicians and nurses from hospitals and primary healthcare centers nationwide report annually to the NDR. Body mass index (BMI), [7] .
Patients, Study Period, Follow-Up, and Censoring
We included patients with type 1 diabetes who were at least 18 years old and had used DAIs continuously for at least 1 year (Fig. 1 History of atrial fibrillation, congestive heart failure, stroke, kidney failure, hyperglycemia, and hypoglycemia was defined in a similar manner using International Classification of Diseases (ICD) 10 codes (Table 1) .
Outcomes
We examined annual changes in mean HbA1c and weight. The safety outcomes were hospitalization due to hyperglycemia or hypoglycemia, kidney failure, CVEs (CHD, CVD, stroke, atrial fibrillation, or congestive heart failure) or death. Except for death, these outcomes are defined using the same ICD codes as described in the section on patient characteristics (Table 1) .
Statistical Methods
Missing baseline data were assigned values by means of multiple imputations from a multivariate normal model using a Monte Carlo Markov chain approach, creating ten data sets. The percentage of missing data ranged from zero (age, gender, treatment, and prior conditions) to 76% (physical activity).
Propensity scores [10] were estimated using a multinomial generalized boosted regression model [11] , including all variables in Table 2 for each imputed data set. The inverse of the average propensity score was used for inverse probability of treatment weighting to adjust for differences in baseline characteristics between treatment groups.
Patient characteristics at baseline were evaluated by means of standard descriptive 
RESULTS
We included 41,165 patients: 14,047 lispro, 26,813 aspart, and 305 glulisine users. We used inverse probability of treatment weighting to adjust for differences in baseline characteristics between the treatment groups.
Prior to the adjustment, there were numerical differences between the groups. Mean age was highest among glulisine users (49.4 years), followed by 41.0 years among lispro users and 40.1 years among aspart users. A total of 9.2% of the patients were 65 years or older. Diabetes duration was shortest among glulisine users A. CHD = groups 0-2 B. CVD = groups 0-4 CABG coronary artery bypass graft, CHD coronary heart disease, CVD cardiovascular disease, ICD10 International Classification of Diseases 10, PCI percutaneous coronary intervention users. A higher proportion of glulisine users had a history of CVD (10.5%), followed by 7.4% among aspart users and 6.5% among lispro users. A lower proportion of glulisine users, however, had a history of severe hypoglycemia (4.3%), followed by 6.2% among aspart users and 7.8% among lispro users. A lower proportion of glulisine users had a history of severe hyperglycemia (5.6%), followed by 8.5% among aspart users and 8.6% among lispro users. The differences between the groups were all adjusted for by means of weighting. The mean follow-up period was shortest for glulisine (2.5 years), followed by 5.8 years for aspart users and 6.4 years for lispro users (Table 3 ). The absolute number of events was very low in the glulisine group, ranging from 0 to 13 ( Values are presented as number of events (incidence per 1000 person-years) unless otherwise stated CHD coronary heart disease, CVD cardiovascular disease Based on these results, insulin glulisine would seem to be superior to the other DAIs in terms of safety, especially in view of the impressive hazard ratios, all of which imply a fivefold-to-tenfold reduction in risk for the outcomes. Are the differences found by the present study accurate? The answer is ''maybe,'' Values are presented as estimated hazard ratios (95% confidence intervals) CHD coronary heart disease, CVD cardiovascular disease, N/A not available a P value \0.05 but caution needs to be exercised not to conclude that any such differences definitely reflect effects of glulisine. For example, the results suggest a more than fivefold reduction of the risk for heart failure among the glulisine group compared to the lispro and aspart groups, even though the effect on HbA1c is the same. If such a reduction in risk is to be attributed to properties of insulin glulisine, there should be evidence of differences in the pharmacological properties of the DAIs. Pharmacological effects and their clinical consequences were reviewed just recently [3] . The general view is that the effects of the three DAIs are highly comparable, with rapid pharmacokinetic (PK) and time-action profiles, although glulisine has been suggested to have a slightly faster onset of action [13] . A trial with insulin lispro and the co-administration of hyaluronidase, which accelerates onset, indicated that a more rapid PK profile could improve control of postprandial hyperglycemia without increasing the risk of hypoglycemia [14] . In other words, faster onset could reduce glucose variability.
However, it is still unclear whether glucose variability increases the risk for diabetic vascular complications [15] . Furthermore, it is unlikely that minor differences in PKs would translate into a pronounced reduction in the risk of heart failure.
The number and the mean follow-up time for glulisine users were also very limited and relatively short compared with those among the other two groups of DAI users. As a result, only three patients in the glulisine group had a heart failure outcome, as opposed to 374 in the lispro group and 743 in the aspart group. There were even fewer events for the sub-analyses. Thus, it is very difficult to objectively compare the risks of outcomes such as heart failure between the three treatment groups. In other words, the the overall cohort and regarding CVD, stroke, and heart failure among the elderly cohort. On the other hand, a higher risk of hyperglycemia was associated with aspart than lispro. As mentioned earlier, there is no known difference in pharmacological effect between these two types of insulin [3] . Thus, these differences are likely due to unobserved confounding.
The only way to confirm whether the observed differences between the safeties of the three DAIs are due to confounding is to conduct a randomized clinical trial (RCT). However, the number of patients and the duration of exposure needed for such a study in order to assess cardiovascular endpoints would probably deter most sponsors. As a result, an RCT of this type is improbable any time soon. Future observational studies are more likely to provide additional data about cardiovascular safety with the types of insulin that are currently available.
Well performed observational studies have been shown to generate results that are comparable to an RCT [16] , although not everyone agrees [17] . The most important limitation of an RCT is the possible lack of external validity. Pharmaceutical agents are frequently used outside of the characteristics of the populations treated in phase 3 programs before registration-hence, our rationale for the sub-analyses in this study of elderly patients and those with reduced renal function.
The major strengths of this study are its nationwide scope, the large number of patients with type 1 diabetes, the relatively long follow-up period, and the many covariates used in the multivariate analyses. As mentioned earlier, the relatively small number and mean follow-up period of insulin glulisine users were limiting factors. 
CONCLUSIONS
In conclusion, we did not find any pronounced differences in effectiveness, long-term cardiovascular safety or mortality between the three available DAIs. Future studies should address the observed differences in the risk of hospitalization for hypoglycemia, hyperglycemia, stroke, and heart failure. The safety profile was also similar in the various subgroups, although the risk of severe hypoglycemia was more common and severe hyperglycemia was less common among elderly patients. Both severe hypoglycemia and severe hyperglycemia were observed more frequently among patients with low renal function.
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